{"organizations": [], "uuid": "bf70d5184bfdf8fd613dd09f56fec72b937d4a98", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180522.html", "section_title": "Archive News &amp; Video for Tuesday, 22 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/cipla-results/update-1-indias-cipla-posts-q4-profit-misses-estimates-idUSL3N1ST3R3", "country": "US", "domain_rank": 408, "title": "UPDATE 1-India's Cipla posts Q4 profit, misses estimates", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-22T19:36:00.000+03:00", "replies_count": 0, "uuid": "bf70d5184bfdf8fd613dd09f56fec72b937d4a98"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/cipla-results/update-1-indias-cipla-posts-q4-profit-misses-estimates-idUSL3N1ST3R3", "ord_in_thread": 0, "title": "UPDATE 1-India's Cipla posts Q4 profit, misses estimates", "locations": [], "entities": {"persons": [{"name": "vyas mohan", "sentiment": "none"}, {"name": "arnab paul", "sentiment": "none"}], "locations": [{"name": "india", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "cipla ltd", "sentiment": "negative"}, {"name": "cipla", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Adds details)\nMay 22 (Reuters) - Cipla Ltd, Indiaâ€™s second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed street estimates.\nNet profit came in at 1.79 billion rupees ($26.30 million) for the quarter ended March 31, compared with a loss of 617.9 million rupees in the year-ago quarter, the company said here\nThat compares with an average 3.57 billion rupees estimated by 16 analysts in a Thomson Reuters poll.\nThe drugmaker recorded an exceptional loss of 775.2 million rupees during the quarter on account of alleged breach of regulatory directives on price control.\nNet sales for the quarter rose marginally to 34.96 billion rupees.\nRevenue from India, its biggest market, grew about 13 percent. Domestic revenues accounted for around a third of its total revenues. ($1 = 68.0650 Indian rupees) (Reporting By Arnab Paul in Bengaluru; Editing by Vyas Mohan)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.bseindia.com/xml-data/corpfiling/AttachLive/2d0d0d7f-af2e-4011-839a-9d5e84a05a76.pdf.", "https://instagram.com/reuters/"], "published": "2018-05-22T19:36:00.000+03:00", "crawled": "2018-05-23T15:09:43.003+03:00", "highlightTitle": ""}